Breast Cancer Trial Results
Hormone Therapy Linked to Modest Increase in Breast Cancer Deaths
(Posted: 10/20/2010) - Women who used combined estrogen and progestin hormone replacement therapy to treat menopausal symptoms during the Women’s Health Initiative (WHI) study had more cases of invasive breast cancer, more lymph-node positive breast cancer, and a slightly higher death rate from breast cancer and other causes than women who received a placebo, researchers reported in an 11-year follow-up report on the study's participants.
For Women with BRCA Mutations, Prophylactic Surgery Reduces Cancer Risk
(Posted: 09/23/2010) - Prophylactic surgery to remove the breasts and ovaries is an effective way to reduce the risk of breast and ovarian cancer among women with inherited mutations in the BRCA1 or BRCA2 genes, according to one of the largest prospective studies on the subject to date.
Single-Dose Partial Breast Irradiation Safe for Some Women with Invasive Breast Cancer
(Posted: 07/08/2010, Updated: 08/04/2010) - A study published online June 5, 2010, in The Lancet shows that for some women with invasive breast cancer a single dose of radiotherapy delivered at the time of surgery may be an alternative to a standard course of external beam radiotherapy.
Some Older Women Can Forgo Radiation after Breast Cancer Surgery
(Posted: 06/22/2010) - Women 70 years of age or older with early-stage breast cancer did not benefit from the addition of radiation therapy to breast-conserving surgery and tamoxifen, according to results of a phase III randomized study presented in advance of the 2010 American Society of Clinical Oncology annual meeting.
Heart Problems From Trastuzumab (Herceptin®) Do Not Increase in the Short Term
(Posted: 06/25/2007, Updated: 06/22/2010) - Women with breast cancer who take the drug trastuzumab (Herceptin®) are at risk of heart problems during treatment. Now a study has shown that the incidence of such problems does not increase in the short term, though the long-term effects remain unknown, according to findings presented at the 2007 ASCO meeting in Chicago.
(Posted: 10/20/2010) - Women who used combined estrogen and progestin hormone replacement therapy to treat menopausal symptoms during the Women’s Health Initiative (WHI) study had more cases of invasive breast cancer, more lymph-node positive breast cancer, and a slightly higher death rate from breast cancer and other causes than women who received a placebo, researchers reported in an 11-year follow-up report on the study's participants.
For Women with BRCA Mutations, Prophylactic Surgery Reduces Cancer Risk
(Posted: 09/23/2010) - Prophylactic surgery to remove the breasts and ovaries is an effective way to reduce the risk of breast and ovarian cancer among women with inherited mutations in the BRCA1 or BRCA2 genes, according to one of the largest prospective studies on the subject to date.
Single-Dose Partial Breast Irradiation Safe for Some Women with Invasive Breast Cancer
(Posted: 07/08/2010, Updated: 08/04/2010) - A study published online June 5, 2010, in The Lancet shows that for some women with invasive breast cancer a single dose of radiotherapy delivered at the time of surgery may be an alternative to a standard course of external beam radiotherapy.
Some Older Women Can Forgo Radiation after Breast Cancer Surgery
(Posted: 06/22/2010) - Women 70 years of age or older with early-stage breast cancer did not benefit from the addition of radiation therapy to breast-conserving surgery and tamoxifen, according to results of a phase III randomized study presented in advance of the 2010 American Society of Clinical Oncology annual meeting.
Heart Problems From Trastuzumab (Herceptin®) Do Not Increase in the Short Term
(Posted: 06/25/2007, Updated: 06/22/2010) - Women with breast cancer who take the drug trastuzumab (Herceptin®) are at risk of heart problems during treatment. Now a study has shown that the incidence of such problems does not increase in the short term, though the long-term effects remain unknown, according to findings presented at the 2007 ASCO meeting in Chicago.
